Financial Performance - For the three months ended September 30, 2021, the revenue was HKD 131,242,000, a decrease of 74.6% compared to HKD 515,725,000 in the same period of 2020[7]. - The gross profit for the same period was HKD 77,051,000, down 70.7% from HKD 263,125,000 year-on-year[7]. - Operating profit for the three months was HKD 32,179,000, a decline of 85.5% compared to HKD 222,058,000 in the previous year[7]. - The net profit for the three months was HKD 22,901,000, a decrease of 87.3% from HKD 179,322,000 in the same quarter of 2020[7]. - The total comprehensive income for the three months was HKD 71,666,000, down 60.1% from HKD 179,444,000 year-on-year[14]. - For the nine months ended September 30, 2021, the revenue was HKD 505,401,000, a decrease of 7.6% compared to HKD 547,030,000 in the same period of 2020[7]. - The operating profit for the nine months was HKD 179,463,000, an increase of 0.8% from HKD 177,966,000 year-on-year[7]. - The net profit for the nine months was HKD 131,891,000, a decrease of 1.2% compared to HKD 133,543,000 in the previous year[7]. - The basic and diluted earnings per share for the three months was HKD 0.003, down from HKD 0.064 in the same period of 2020[14]. - The company's profit attributable to owners for the nine months ended September 30, 2021, was HKD 27,254,000, compared to HKD 21,532,000 for the same period last year, reflecting a 26.5% increase[42]. - Basic and diluted earnings per share for the nine months ended September 30, 2021, were HKD 0.028, up from HKD 0.022 in the same period last year, indicating a 27.3% increase[42]. Revenue Streams - For the nine months ended September 30, 2021, the revenue from medical laboratory testing services and health check services was HKD 491.61 million, compared to HKD 539.26 million for the same period in 2020, reflecting a decrease of approximately 8.8%[26]. - The revenue from insurance brokerage services for the nine months ended September 30, 2021, was HKD 6.42 million, an increase of approximately 6.2% from HKD 6.05 million in the same period of 2020[26]. - The revenue from logistics services for the nine months ended September 30, 2021, was HKD 6.32 million, with no revenue reported in the same period of 2020, indicating a new revenue stream[26]. - The total revenue for the nine months ended September 30, 2021, was HKD 547.03 million, compared to HKD 505.40 million for the same period in 2020, representing an increase of approximately 8.3%[26]. - The company reported a significant decrease in revenue from the manufacturing and sales of health-related and pharmaceutical products, with no revenue recorded for the three months ended September 30, 2021, compared to HKD 161,000 in the same period of 2020[26]. Operational Developments - The company continues to focus on expanding its services in tumor immunotherapy and health management services in China, which are key areas of growth[21]. - The company operates primarily in tumor immunotherapy, health management services, and medical laboratory testing in China and Hong Kong[49]. - The group has established a basic laboratory in Hong Kong to provide COVID-19 nucleic acid testing services, and a mobile laboratory at Hong Kong International Airport for rapid testing[50]. - Shanghai Longyao has initiated clinical research for a new CAR-T therapy, LY007, which received approval for clinical trials in January 2021[52]. - The company is exploring diversification in its testing business and plans to expedite the Phase I clinical trials for CAR-T products that have received clinical approval[72]. Shareholder Information - As of September 30, 2021, the total number of issued shares of the company was 963,231,150, with a par value of HKD 0.10 per share[79]. - Mr. Liu Xiaolin holds 529,500,546 shares, representing approximately 54.97% of the company's total shares[78]. - Genius Earn, a controlled corporation, also holds 529,500,546 shares, equivalent to 54.97%[83]. - Guoyuan Securities Investment (Hong Kong) Limited holds 22,428,571 shares, accounting for 2.33% of the total shares[83]. - Guoyuan International Holdings Limited has a controlled interest in 475,082,640 shares, representing 49.32%[83]. - The total number of options granted under the share option scheme is 13,760,000, which is approximately 1.44% of the total shares[81]. - The company has implemented a share option scheme to reward eligible participants for their contributions to the group's success[87]. - The company has a significant concentration of ownership, with major shareholders holding over 54% of the total shares[84]. Corporate Governance - The company maintained compliance with the GEM Listing Rules regarding corporate governance during Q3 2021[109]. - The audit committee, consisting of three independent non-executive directors, reviewed the financial reporting procedures and internal controls for Q3 2021[111]. - The company confirmed that all directors adhered to the trading standards and code of conduct during Q3 2021[107]. - The company expressed gratitude to stakeholders for their support in the Q3 2021 report[114]. Financial Costs and Income - Interest income for the three months ended September 30, 2021, was HKD 1,000, down from HKD 4,000 in the same period last year, representing a 75% decrease[29]. - Miscellaneous income increased significantly to HKD 171,000 for the three months ended September 30, 2021, compared to HKD 55,000 in the same period last year, marking a 210.9% increase[29]. - Total financing costs for the three months ended September 30, 2021, were HKD 1,210,000, a decrease of 47.5% from HKD 2,307,000 in the same period last year[30]. - Financing costs increased to approximately HKD 5,286,000 in Q3 2021, compared to HKD 4,180,000 in Q3 2020[63]. Market Outlook - The economic outlook for the coming year is expected to improve slightly despite ongoing geopolitical and macroeconomic challenges[70]. - The global CAR-T market is projected to grow at a compound annual growth rate of 59%, reaching USD 8.71606 billion by 2025[71].
中国生物科技服务(08037) - 2021 Q3 - 季度财报